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Abstract
Early (one year) and late (15 year) outcomes after heart 
transplantation in Malta were evaluated by means of a 
retrospective analysis of mortality and morbidity, derived from 
the transplant database. Fifteen transplants were performed 
with an 87% operative and one-year survival and an 80% 15-year 
survival.  Four patients experienced complications necessitating 
major surgical interventions and 5 further patients required 
hospital admission for other complications. Four patients never 
required hospital admission after their transplant. Twelve long-
term survivors enjoy an unrestricted life, whereas one patient is 
troubled with recurrent gout. Results of heart transplantation 
can be gratifying, even when performed in a low-volume centre.
Introduction
Cardiac transplantation may become the treatment of choice 
for selected patients suffering from severe, end-stage heart 
failure, unresponsive to maximal medical therapy. In recent 
years worldwide transplantation rates have reached a plateau, 
with potential recipients outstripping available donors by a 
factor of ten.1 Some countries, such as the UK, have experienced 
a decline of 50% over the last ten years, triggering a review of 
the number of transplant centres.2 Recent evidence has linked 
early survival to transplant centre volume, citing a higher risk 
of early mortality in lower-volume centres.3 
This study sets out to demonstrate that short- and long-term 
survival can be achieved in a low-volume transplant centre.
The population of Malta is close to 400,000 and cardiac 
transplants are performed at a rate of approximately one per 
year. The Maltese cardiac transplant program qualifies as a 
very low-volume centre and figures are not likely to increase 
due to global as well as local factors. Six adult transplant 
centres support a country like the UK, with a population of 60 
million, with specialist skills and resources spread across the 
country. One hundred and twenty transplants were performed 
in 2009-2010, a rate of 2 per million population (range 4-23 
transplants per unit).4 Italy and Germany both support 8 heart 
transplant units with similar transplant rates. Our local rate of 
transplantation is not significantly different.
Methods
Preparation
The local transplant program began in 1995 soon after the 
establishment of our general cardiothoracic program. Protocols 
were drawn up and a pathologist was trained overseas in the 
interpretation myocardial biopsies. The laboratory made plans 
for the provision of an emergency service for cyclosporine 
level estimation. Special arrangements were made for a single 
intensive care room with reverse barrier nursing facilities. Close 
collaboration with cardiology was established for the serial 
measurements of pulmonary vascular resistance and post-
operative myocardial biopsies. A suitable recipient was identified 
and a donor became available on the 25th September 1996, 
when the first successful orthotopic transplant was performed. 
Recipients
All potential recipients were referred to the program 
either via the cardiology department or were identified by us 
as transplant candidates after they had been referred for a 
diverse surgical procedure. These latter patients were then 
referred to cardiology for further evaluation before being 
considered potentially suitable candidates. In the late 1990’s 
patients were referred after failure of standard medical 
treatment for heart failure, be it secondary to ischaemic heart 
disease or cardiomyopathy. In recent years more patients have 
enjoyed the benefits of improved medical treatment with ACE 
inhibitors, spironolactone, beta-blockers and ivabradine, as 
well as re-synchronisation therapy, sometimes combined with 
an implantable defibrillator. An improvement in their heart 
failure class has often translated into a delay in placing on, or a 
withdrawal of these patients from our active list.
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Donors
All potential donors were referred to us from the general 
intensive care unit after they had been declared brain dead 
and consent for organ donation had been obtained. Qualified 
specialists performed the brain death tests on two separate 
occasions, after all biochemical and other relevant abnormalities 
had been corrected. Once a donor’s organs were deemed 
acceptable for transplantation, a suitable recipient was alerted 
and admitted to hospital when a further right heart study was 
performed where indicated. Coordination with other retrieval 
teams, often from abroad, was effected via the transplant 
coordinator and all interested parties then worked towards a 
common goal and a set program. In Malta we practice an opt-in 
system of donation.5
Method of transplantation and aftercare
All patients received an orthotopic transplant and all donor 
hearts were retrieval locally, obviating the need for distant 
procurement. Surgery was performed at normothermia and 
according to the methods described by Brock and Shumway.6 
Temporary dual chamber pacing leads were routinely 
implanted and the patient was nursed post-operatively in a 
single cubicle with reverse barrier precautions. Triple therapy 
immunosuppression was administered and prolonged inotropic 
and chronotropic support was usually necessary. Patients were 
discharged from hospital when they were mobile and after two 
satisfactory biopsy results. Aftercare was comprehensive, with 
open channels for patient communication, regular follow-up, 
and programmed biopsies. Our department worked closely 
with the departments of cardiology, infectious diseases and 
renal medicine.
Haemodynamic measurements
Pulmonary vascular resistance (PVR) was calculated by 
measuring the trans-pulmonary gradient (mean pulmonary 
artery pressure minus pulmonary capillary wedge pressure) in 
mmHg, and dividing this by the cardiac output (measured by 
the thermodilution method) in l/min. PVR is given in mmHg.
min/l, also known as Wood units.
Statistics
Continuous variables were expressed as mean±standard 
deviation (SD) and the Student’s t-test was used to compare 
means. SPSS 13.0 (Chicago, IL) was used for computation. 
Statistical significance was accepted at a level of p<0.05.
Results
Fourteen transplants were performed in Malta, and a further 
transplant performed jointly at Great Ormond Street Hospital, 
London, on a Maltese adolescent with congenital heart disease, 
who receives his medical follow-up locally. 
Mortality 
The survival curve is shown in Figure 1. Early survival was 
87% and late survival, at fifteen years 80%. 
There were two operative deaths, both due to pulmonary 
hypertension and acute right ventricular failure.7 One patient 
was a 23-year-old man of South American origin who had 
dilated cardiomyopathy and a pulmonary vascular resistance of 
3.6 Wood units. He was in cardiogenic shock on an intra-aortic 
balloon pump at the time of transplantation. The other patient 
was a 62-year-old man who had undergone a coronary bypass 
operation four years previously and presented with heart failure. 
His pulmonary vascular resistance was 3.0 Wood units. 
One late death occurred in a 56-year-old man (patient 
6, Table 1), eight years after transplantation, due to graft 
vasculopathy8 and heart failure. This patient required several 
admissions for treatment of heart failure during his last year of 
life and underwent coronary angioplasty with stenting.
Major morbidity 
Patient clinical summaries are presented in Table 1. Nine 
patients were readmitted at some time in their post-operative 
course. 
Seven patients required further surgery, four after major 
complications, as follows: 
•   Patient 4 developed post-operative suppurative 
mediastinitis and underwent re-sternotomy, debridement 
and irrigation, with good result. 
•   Three patients required major abdominal surgery: 
-  Patient 10 underwent appendicectomy for acute 
appendicitis one year after transplantation. He 
presented with a purulent discharge from the biopsy 
entry-point in his groin.
-   Patient 11 underwent salpingo-oophorectomy for 
a pelvic abscess two years after transplantation. 
She presented with pyrexia of unknown origin and 
ultrasound revealed Fallopian tube pathology. 
Figure 1: Actuarial survival
Legend: Figures bellow graph for local group show numbers 
of patients at risk. ISHLT: International Society for Heart and Lung 
Transplantation Registry 
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-   Patient 13 underwent emergency left hemicolectomy 
for diverticulitis complicated by massive intestinal 
bleeding, six months after transplant. His colostomy 
was reversed successfully 6 months later.
• Three further patients required surgery:
- Patient 1 required several excisions of cutaneous basal 
cell and squamous cell carcinomas, as well as cervical 
lymph node biopsy and radiotherapy, fourteen years 
after transplant. His condition is now under control.
-   Patient 3 required excision of a basal cell carcinoma, 
as well as insertion of a catheter for peritoneal dialysis 
twelve years after transplant. He is awaiting kidney 
transplantation.
-  Patient 8 required trans-urethral resection of 
the prostate for benign disease, three years after 
transplant.
•   Other hospital admissions were due to the following:
-  Patient 2 required admission for acute renal failure as 
well as non-compliance with medication, secondary 
to depression, ten years after transplant. This was 
successfully resolved and he remains well.
-  Patient 8 required admission for treatment of 
Pneumocystis jiroveci pneumonia, while patients 
11, 12 and 13 required readmission for treatment of 
cytomegalovirus infection/reactivation, all within six 
months after transplant.
Post-operative course
No formal quality of life assessment was undertaken.9 
Twelve patients enjoy an unrestricted life. Patient 10 suffers 
from recurrent episodes of gout, curtailing quality of life and 
requiring medication for symptom relief.
Four males are gainfully employed and one female leads a 
busy life as a housewife. Eight patients have traveled abroad 
since their transplant, five of these on multiple occasions. Four 
patients suffered no major late complications and have never 
been readmitted to hospital since their transplant, except as 
a day case for myocardial biopsy and coronary angiography 
as indicated. Although four patients suffered complications 
requiring major surgery, three of them experienced short-lived 
morbidity and their post-operative recovery was swift. Patient 
13 was subjected to a colostomy for 6 months before this was 
successfully reversed.
Myocardial biopsies
The number of biopsies performed during the first year 
averaged 8 (Figure 2). Patients generally underwent one biopsy 
per annum in subsequent years. Patients who developed serious 
rejection of grade 3A and above had significantly higher white 
cell counts as a group (6.71±2.19 x109/l), than those that did 
not develop serious rejection (4.96±1.62 x109/l, p<0.0001).
Coronary angiography
All patients underwent coronary angiography on one 
or more occasions once three years had elapsed from their 
transplant. Of the ten patients who underwent angiography, 
patient 6 had severe diffuse coronary artery disease consistent 
with graft vasculopathy.  He had suffered two episodes of severe 
rejection after poor compliance with his immunosuppressant 
medications. He underwent angioplasty and stenting but his 
disease progressed and he died 8 years after his transplant. 
Patient 2 was found to have moderate disease in two obtuse 
marginal arteries and remains under review. The eight other 
coronary angiograms were either normal or showed mild, non-
significant disease.  
Patient Age Transplantyear Rejection Creatinine Admission Complications
1 52 1996 nil - + skin carcinoma*, gout
2 54 1997 1 + + depression, gout, prostatitis, mild CAD
3 52 1998 nil + + CAPD*, BCC*
4 62 1999 nil - - mediastinitis**, gout, orchitis
5 15 2000 nil - - nil
6 48 2000 2 - + graft vasculopathy, CMV, died at 8 
years
7 48 2001 nil - - nil
8 57 2005 1 - + pneumocystitis jiroveci, TURP*
9 60 2006 1 - - herpes zoster
10 63 2007 1 - + appendicitis**, severe gout
11 34 2009 1 - + pelvic abscess**, CMV
12 57 2010 nil - + CMV
13 62 2011 nil - + diverticulitis**, CMV
*   requiring surgery    ** requiring major surgery
Table 1: Clinical summary
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Renal function
There was a gradual rise in creatinine levels with passing 
years (Figure 3). Two patients developed a creatinine level over 
300μmol/L and one is on chronic ambulatory peritoneal dialysis 
awaiting renal transplantation. Cyclosporine toxicity did not 
play a role as levels were lower in these two patients (104±44 
ng/ml versus 118±35 ng/ml in the rest). 
Immunosuppression
All patients were started on triple immunosuppression 
therapy with intravenous methylprednisolone, and oral 
azathioprine and cyclosporine. Within a few days the steroids 
were changed to oral prednisolone, which was tailed off 
gradually over a mean of 4 years (range 2-7 years), depending 
on biopsy results and clinical course. Azathioprine was 
changed to mycofenolate sodium in one patient because of 
hepatotoxicity. In another patient with gout, azathioprine was 
also temporarily changed to mycofenolate when allopurinol was 
introduced but renal function deteriorated and medication was 
reverted with improvement. A third patient also discontinued 
azathioprine because of pancytopaenia and subsequently had his 
cyclosporine changed to sirolimus after he developed squamous 
cell carcinoma of the skin. All other patients were managed on 
long-term azathioprine and cyclosporine. 
Other medications
Standard medications included aspirin, nystatin syrup, 
co-trimoxazole, perindopril, and statins. Fluvastatin was 
the preferred statin in view of possible interactions of other 
statins with cyclosporine.10 Angiotensin receptor blockers have 
recently been withheld because of reports of a possible increased 
incidence of thoracic tumours in smoking transplantees.11 
Discussion
Declining transplant numbers in the UK, blamed on a 
scarcity of intensive care beds, have triggered a downward 
review of the number of transplant centres. The UK Health 
Department stated that surgeons might experience difficulties 
in maintaining competence in a contracting practice.12  A study 
by Shuhaiber et al3 concluded that early mortality was higher in 
very low-volume transplant centres when compared with higher 
volume centres. A similar study by Hosenpud et al13 showed 
a significantly higher early and one-year mortality in centres 
performing fewer than nine transplants per year, and that these 
units made up more than half the US transplant centres. Davies 
et al concluded that short- and long-term survival in paediatric 
heart transplantation was significantly lower in low-volume 
centres.14 Worldwide figures15 as well as single centre studies16 
show a survival of 50% at 10 years (Figure 1). Our unit qualifies 
as a very low-volume transplant centre and yet our 10-year 
survival stands at 80%. Several factors may account for this, not 
least the fact that we do not practice distant retrieval. Moreover 
patient contact is very thorough and any complication is dealt 
with expeditiously. Following the two operative deaths from 
pulmonary hypertension we altered our acceptance criteria for 
potential recipients to those with a PVR of less than 2.5 Wood 
units, even if this was achieved after maximal oral vasodilator 
therapy.  
In the patients who developed abdominal complications, 
presentation was unusual. Thus the patient who developed 
appendicitis presented with a purulent discharge from a recent 
groin entry point used for myocardial biopsy. At surgery a 
gangrenous appendix was removed. Similarly the patient who 
developed a pelvic abscess secondary to an infected ovarian 
cyst experienced no abdominal pain and presented with 
pyrexia of unknown origin. The patient who underwent left 
hemicolectomy for extensive diverticulitis presented with mild 
rectal bleeding which increased dramatically over the course of 
a day. Abdominal complications are a recognised feature in the 
early post-transplant course. Five to ten percent of transplantees 
require laparotomy to establish a prompt diagnosis and the 
procedure is well tolerated.17,18
Figure 2: Biopsies performed during the first year
* four further biopsies performed at GOS Hospital, London
Figure 3: Creatinine levels
34 Malta Medical Journal    Volume 24   Issue 02  2012
Cytomegalovirus (CMV) infection is the single most 
important viral infection in heart transplant recipients, and 
is most prevalent in the first year.19,20 Two of the four patients 
who developed CMV infection were sero-negative before 
transplantation and received a sero-positive heart (D+/R-). 
Patient 11 presented with severe abdominal pain and patient 
12 with headaches. Patients 6 and 13 developed a reactivation 
infection, both presenting with pyrexia. All patients received 
intravenous ganciclovir until the polymerase chain reaction 
(PCR assay) became negative, followed by a nine-week course 
of oral valganciclovir treatment.21
Nephrotoxicity is a well-recognised complication of 
long-term cyclosporine use. Two of our patients developed a 
creatinine level of over 300μmol/L and one is on peritoneal 
dialysis. In our series cyclosporine remained the calcineurin 
inhibitor of choice because of its proven long-term allograft 
survival with adequacy of renal function.22 Reduction in 
cyclosporine dose is associated with an increased rate of rejection 
events.23 Reducing the cyclosporine dose and substituting the 
azathioprine for mycofenolate24 may improve renal function. 
Newer immunosuppressive agents, such as sirolimus and 
tacrolimus may play a role in this setting.25
Conclusion
Heart transplantation is an effective modality of treatment 
for certain patients with refractory heart failure. Long-term 
survival can be achieved in a high proportion of patients. 
Outcomes are not necessarily related to transplant volume.
References
1. 1.Taylor DO, Edwards LB, Boucek MM, Trulock EP, Aurora 
P, Christie J, et al. Registry of the International Society for 
Heart and Lung Transplantation: twenty-fourth official adult 
heart transplant report - 2007. J Heart Lung Transplant. 
2007;26(8):769-81.
2. NHS blood and transplant annual report 2009/10. Transplant 
activity in the UK. Available at: http://www.organdonation.nhs.
uk/ukt/statistics/transplant_activity_report/current_
3. activity_ reports/ukt/activity_report_2009_10.pdf. 
4. Shuhaiber JH,  Moore J,  Dyke DB. The effect of transplant center 
volume on survival after heart transplantation: A multicenter 
study. J Thorac Cardiovasc Surg. 2010;139:1064-9. 
5. NHS Blood and Transplant registry website. Available at: http://
www.organdonation. nhs.uk [Accessed: April 2012].
6. Lauri MA, Zarb Adami J. The need for increasing the retrieval 
of organs: doctors’ attitudes towards opting-out. Malta Med J. 
2010;4:14-9.
7. Meine TJ, Russel S. A history of orthotopic heart transplantation. 
Cardiol Rev. 2005;13:190-6.
8. Chen JM, Levin HR, Michler RE, Prusmack CJ, Rose EA, 
Aaronson KD. Reevaluating the significance of pulmonary 
hypertension before cardiac transplantation: Determination 
of optimal thresholds and quantification of the effect of 
reversibility on perioperative mortality. J Thorac Cardiovasc Surg. 
1997;114:627-34.
9. Labarrere CA, Woods JR, Hardin JW, Campana GL, Ortiz MA, 
Jaeger BR, et al. Early prediction of cardiac allograft vasculopathy 
and heart transplant failure. Am J Transpl. 2011;11:528-35. 
10. de Jeu JH, Pedersen SS, Balk AHMM, van Domburg RT, 
Vantrimpont PJMJ, Erdman RAM. Development of the 
Rotterdam Quality of Life questionnaire for heart transplant 
recipients. Netherlands Heart J. 2003;11:289-93.
11. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics 
of the HMG-CoA reductase inhibitors. Similarities and 
differences. Clin Pharmacokinetics. 1997;32:403-25.
12. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. 
Angiotensin-receptor blockade and risk of cancer: meta-analysis 
of randomised controlled trials. Lancet Oncol. 2010;11(7): 627-36.
13. MacGowan GA, Parry G, Schueler S, Hasan A. The decline in 
heart transplantation in the UK. BMJ. 2011;342:2483-4.
14. Hosenpud JD, Breen TJ, Edwards EB, Daily P, Hunsicker LG. The 
effect of transplant center volume on cardiac transplant outcome. 
JAMA. 1994;27:1844-9.
15. Davies RR, Russo MJ, Hong KN, Mital S, Mosca RS, Quaegebeur 
JM et al. Increased short- and long-term mortality at low-volume 
pediatric heart transplant centres: should minimum standards be 
set? Retrospective data analysis. Ann Surg. 2011;253:393-401.
16. Stehlik J, Edwards LB, Kucheryavaya AY, Aurora P, Christie JD, 
Kirk R, et al. The Registry of the International Society of Heart 
and Lung Transplantation: twenty-seventh official adult heart 
transplant report - 2010. J Heart Lung Transplant. 2010;29:1089-
103.
17. 16. Fraund S, Pethig K, Franke U, Wahlers T, Harringer W, 
Cremer J et al. Ten year survival after heart transplantation: 
palliative procedure or successful long term treatment? Heart. 
1999;82:47–51. 
18. Watson CJE, Jamieson NV, Johnston PS, Wreghitt T, Large S, 
Wallwork J et al. Early abdominal complications following heart 
and heart–lung transplantation. B J Surg. 1991;78:699-704.
19. Merrell SW, Ames SA, Nelson EW, Renlund DG, Karwande 
SV, Burton NA et al. Major abdominal complications following 
cardiac transplantation. Utah Transplantation Affiliated Hospitals 
Cardiac Transplant Program. Arch Surg. 1989;124:889-94.
20. Highlights From The Sixth Annual AST Winter Symposium  
- Transplantation Meets Infection: Microbes, Rejection, 
Atherosclerosis, and Malignancy; January 17-20, 2002; Squaw 
Creek, Olympic Valley, California. Available at: http://www.
medscape.com/view article/424607
21. Avery RK. The relationship between cytomegalovirus and 
chronic allograft dysfunction. Clinical Update. Medscape 
Transplantation. 2000. Available at: http://www.medscape.com/ 
viewprogram/282
22. Reusser P. Oral valganciclovir: a new option for treatment of 
cytomegalovirus infection and disease in immunocompromised 
hosts. Exp Opin Investig Drugs. 2001;10:1745-53.
23. Goral S, Ynares C, Shyr Y, Yeoh TK, Johnson HK. Long-term 
survival in heart transplant recipients receiving cyclosporine 
therapy. J Heart Lung Transplant. 1997;16:1106-12.
24. Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Druser R, Cohen 
D. Cyclosporine-associated end-stage nephropathy after cardiac 
transplantation. Transplantation. 1997;63:664-8.
25. Aleksic I, Barylei M, Busch T, Pieske B, Schorn B, Strauch J et 
al. Improvement of impaired renal function in heart transplant 
recipients treated with mycophenolate mofetil and low-dose 
cyclosporine. Transplantation. 2000;69:1586-90.
26. Morelon E, Mamzer-Bruneel MF, Peraldi MN, Kreis H. Sirolimus: 
a new promising immunosuppressive drug. Towards a rationale 
for its use in renal transplantation. Nephrol Dial Transplant. 
2001;16:18-20.  
